Tuesday, 10 November 2026
Virtual care standards review, Financial interest disclosure rules, ADHD directory access gaps
- 01
Draft virtual-care standards could underpin national accreditation scheme
Draft national standards for virtual care have been released for review, with the framework intended to apply in any healthcare setting where virtual care is provided and potentially support a future accreditation scheme. The Australian Commission on Safety and Quality in Health Care draft covers clinical governance, person-centred practice and safe clinical systems, including use of at least three approved patient identifiers at registration and the start of care. It also stipulates that systems support accurate history-taking and assessment when prescribing, and that treatment decisions align with best practice and remain free from commercial influence. There are currently no endorsed standards for telehealth-only providers, and the Commission said providers would be encouraged to implement the standards while it considers assessment options, including accreditation. Consultation feedback closed on 13 December, and the final standards are expected in late 2027.
via RACGP newsGP · also covered by The Medical Republic
- 02
AHPRA clarifies disclosure rules for doctors’ financial interests
Doctors who benefit financially from referrals to pathology, imaging or other healthcare businesses must disclose those arrangements under interim AHPRA guidance. The regulator said practitioners must identify, disclose and appropriately manage interests that could influence clinical decisions, with patient welfare taking priority over commercial interests. The guidance is particularly relevant to co-located services and reinforces that patients must understand the financial interest, available alternatives and their freedom to use another provider. Medicolegal expert Anthony Mennillo said disclosure alone might not resolve a conflict and relevant disclosures should also be recorded in the patient’s medical record. The interim guidance reinforces existing professional obligations while AHPRA and the National Boards conduct a broader review of codes of conduct.
- 03
Victorian ADHD directory lists unavailable clinics after pathway expansion
Following NSW’s expansion of GP ADHD authority, Victoria’s newly launched pathway opened with a directory listing at least 15 services that were not accepting program patients, including one that had closed, while omitting some participating clinics. From 26 October, 150 newly trained Victorian GPs could diagnose, treat and prescribe ADHD medication for adults and children aged six and older. Fourteen services were removed and five added after the launch, while some listed sites offered no GP services or did not book consultations, according to Nine Newspapers. A Victorian government spokesperson said clinics could be removed when participating GPs reached capacity and restored when capacity increased. RACGP Victoria chair Dr Anita Muñoz said the initial GP cohort would not meaningfully change access until the trained workforce increased four- or fivefold.
- 04
Vir combination met all endpoints in phase 3 hepatitis D trial
Vir Biotechnology’s experimental combination of elebsiran and tobevibart met all objectives in the first of three phase 3 trials in chronic hepatitis D. After 48 weeks, 44% of treated participants had largely eliminated detectable signs of the virus and normalised levels of an important liver enzyme, compared with none in a delayed-treatment cohort. The regimen also met a key secondary endpoint, with 79% of treated patients achieving a response based on reduced viral levels. Two further phase 3 trials are ongoing, with data expected early next year; positive results from all three would support a regulatory submission in 2027. Chronic hepatitis D occurs only in people with hepatitis B and has limited treatment options.
via BioPharma Dive
- 05
India proposes immediate licence suspensions after failed drug quality checks
India’s proposed rules would empower drug regulators to immediately suspend manufacturing licences when medicines fail routine government quality checks. The change aims to tackle quality lapses in a pharmaceutical industry that accounted for an estimated 20% of global generic medicine supplies in 2023. Recent health alerts involved Indian-made cough syrups linked to child deaths in the Gambia, Uzbekistan and India, and eye drops linked to bacterial infections in the US. Concerns also arose over intravenous fluid quality after four women died in Karnataka in 2024.
via BMJ
- 06
Eugia recalls vancomycin injection lot over particulate matter
Eugia US LLC voluntarily recalled lot 3VM26026A of Vancomycin Hydrochloride for Injection USP 1.25 g/vial in 30 mL single-dose vials because of particulate matter. The nationwide US recall, announced on 6 November 2026, extends to hospitals, healthcare facilities and users. The source gives limited detail beyond the affected product, lot and reason for recall.
via FDA MedWatch
MDDR is a news digest for medical professionals. It is not medical advice and should not be relied on for clinical decision-making.